MBX 2982

Drug Profile

MBX 2982

Alternative Names: MBX-2982; SAR-260093

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabolex
  • Developer CymaBay Therapeutics
  • Class Antihyperglycaemics; Pyrimidines; Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 10 Dec 2013 Metabolex is now called CymaBay Therapeutics
  • 28 Apr 2011 MBX 2982 is no longer licensed to sanofi-aventis worldwide
  • 18 Aug 2010 Metabolex completes a phase II trial (NCT01035879) in Type-2 diabetes mellitus in USA, Georgia and India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top